LONITEN 2.5MG TABLET

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

MINOXIDIL

Διαθέσιμο από:

PFIZER CANADA ULC

Φαρμακολογική κατηγορία (ATC):

C02DC01

INN (Διεθνής Όνομα):

MINOXIDIL

Δοσολογία:

2.5MG

Φαρμακοτεχνική μορφή:

TABLET

Σύνθεση:

MINOXIDIL 2.5MG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

100

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

DIRECT VASODILATORS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0114429002; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

1998-05-04

Αρχείο Π.Χ.Π.

_LONITEN (minoxidil tablets USP) Product Monograph _
_ Page 1 of 25 _
PRODUCT MONOGRAPH
PR
LONITEN
®
(Minoxidil Tablets USP)
2.5 mg and 10 mg
ANTIHYPERTENSIVE
®
TM Pharmacia & Upjohn Company LLC
Pfizer Canada Inc., Licensee
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
November 14, 2013
©
Pfizer Canada Inc. 2013
SUBMISSION CONTROL NO: 167423
_LONITEN (minoxidil tablets USP) Product Monograph _
_ Page 2 of 25 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................................15
DETAILED PHARMACOLOGY
......................................